U.S. markets open in 53 minutes
  • S&P Futures

    3,876.25
    +8.75 (+0.23%)
     
  • Dow Futures

    31,472.00
    +114.00 (+0.36%)
     
  • Nasdaq Futures

    13,082.00
    +26.75 (+0.20%)
     
  • Russell 2000 Futures

    2,245.20
    +16.10 (+0.72%)
     
  • Crude Oil

    60.37
    +0.62 (+1.04%)
     
  • Gold

    1,707.50
    -26.10 (-1.51%)
     
  • Silver

    26.22
    -0.66 (-2.47%)
     
  • EUR/USD

    1.2053
    -0.0035 (-0.29%)
     
  • 10-Yr Bond

    1.4640
    +0.0490 (+3.46%)
     
  • Vix

    23.73
    +0.38 (+1.63%)
     
  • GBP/USD

    1.3960
    +0.0004 (+0.03%)
     
  • USD/JPY

    106.9220
    +0.2120 (+0.20%)
     
  • BTC-USD

    51,869.55
    +3,143.89 (+6.45%)
     
  • CMC Crypto 200

    1,037.22
    +49.12 (+4.97%)
     
  • FTSE 100

    6,652.61
    +38.86 (+0.59%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 9199546. To access a live webcast and subsequent archived recording of the call, please visit the "Investors & Media" section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005165/en/

Contacts

Loraine Spreen
loraine.spreen@kalarx.com
857-277-4842

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200